Abstract
Objectives: Mortality among patients with carbapenem-resistant Acinetobacter baumannii (CRAB) infections varies between studies. We examined whether in vivo fitness of CRAB strains is associated with clinical outcomes in patients with CRAB infections. Methods: Isolates were collected from patients enrolled in the AIDA trial with hospital-acquired pneumonia, bloodstream infections and/or urinary tract infections caused by CRAB. The primary outcome was 14-day clinical failure, defined as failure to meet all criteria: alive; haemodynamically stable; improved or stable Sequential Organ Failure Assessment (SOFA) score; improved or stable oxygenation; and microbiological cure of bacteraemia. The secondary outcome was 14-day mortality. We tested in vivo growth using a neutropenic murine thigh infection model. Fitness was defined based on the CFU count 24 hours after injection of an inoculum of 105 CFU. We used mixed-effects logistic regression to test the association between fitness and the two outcomes. Results: The sample included 266 patients; 215 (80.8%) experienced clinical failure. CRAB fitness ranged from 5.23 to 10.08 log CFU/g. The odds of clinical failure increased by 62% for every 1-log CFU/g increase in fitness (OR 1.62, 95% CI 1.04–2.52). After adjusting for age, Charlson score, SOFA score and acquisition in the intensive care unit, fitness remained significant (adjusted OR 1.63, 95% CI 1.03–2.59). CRAB fitness had a similar effect on 14-day mortailty, although the association was not statistically significant (OR 1.56, 95% CI 0.95–2.57). It became significant after adjusting for age, Charlson score, SOFA score and recent surgery (adjusted OR 1.88, 95% CI 1.09–3.25). Conclusions: In vivo CRAB fitness was associated with clinical failure in patients with CRAB infection.
Original language | English |
---|---|
Pages (from-to) | 73-78 |
Number of pages | 6 |
Journal | Clinical Microbiology and Infection |
Volume | 28 |
Issue number | 1 |
DOIs | |
State | Published - Jan 2022 |
Externally published | Yes |
Bibliographical note
Publisher Copyright:© 2021 European Society of Clinical Microbiology and Infectious Diseases
Funding
Part of this work was supported by the European Commission FP7 AIDA project (Preserving old antibiotics for the future: assessment of clinical efficacy by a pharmacokinetic/pharmacodynamic approach to optimize effectiveness and reduce resistance for off-patent antibiotics), Grant Health- F3-2011-278348 . Part of this work was supported by the European Commission FP7 AIDA project (Preserving old antibiotics for the future: assessment of clinical efficacy by a pharmacokinetic/pharmacodynamic approach to optimize effectiveness and reduce resistance for off-patent antibiotics), Grant Health-F3-2011-278348.GLD has received research funding from Pfizer, Achaogen, Rempex, MSD and Gilead. ED-M has received research funding from MSD, Pfizer, Angelini and Correvio. LEF has received research funding from Genentech and acted as an advisor to Pharmetheus. YC has received research funding from MSD, AstraZeneca, Allecra Therapeutics, DaVoltera, Intercell AG, bioM?rieux SA, Rempex Pharmaceuticals, Nariva, Achoagen, Roche, Pfizer and Shionogi. All other authors declare no competing interests.
Funders | Funder number |
---|---|
Allecra Therapeutics | |
Angelini and Correvio | |
Pfizer | |
AstraZeneca | |
Genentech | |
Roche | |
Gilead Sciences | |
Meso Scale Diagnostics | |
European Commission | F3-2011-278348 |
Shionogi |
Keywords
- Bacterial fitness
- Carbapenem-resistant Acinetobacter baumannii
- Clinical outcome
- Murine thigh infection model
- Treatment failure